Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/tbj.13787 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial.
J Natl Cancer Inst
December 2024
Winship Cancer Institute at Emory University, Atlanta, GA, USA.
Article Synopsis
Pathogen class-specific transcriptional responses derived from PBMCs accurately discriminate between fungal, bacterial, and viral infections.
PLoS One
December 2024
Division of Infectious Diseases, Duke University, Durham, North Carolina, United States of America.
Article Synopsis
- Immune responses to acute infections share common elements across different pathogens, which can aid in creating better diagnostics and treatments.
- Analysis of gene expression in white blood cells shows these common patterns, helping to identify the type of infection (viral or bacterial).
- A study identified a 41-gene signature that classifies infections with high accuracy and a smaller 21-gene subset that distinguishes between specific infections, underscoring the potential for developing effective diagnostic tools.
Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial.
Eur J Cancer
December 2024
Department of Medical Oncology, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy. Electronic address:
Background: Data published in 2015 showed that patients with early breast cancer (EBC) and a low-risk (LR) Recurrence Score® (RS) result by the 21-gene Oncotype DX® assay ("the test") did not derive benefit from adding chemotherapy (CT) to endocrine therapy (HT), while those with a high-risk (HR) RS result did. However, the role of CT remained uncertain in patients with intermediate-risk (IR) cancers. We designed a study to assess the test's ability to categorize patients with EBC with uncertain biological behavior into the groups (LR and HR) for which the value of additional chemotherapy was defined.
View Article and Find Full Text PDFThe utility of the 21-gene Oncotype DX Breast Recurrence Score assay in node-negative breast cancer patients - the final analysis of the Polish real-life survey PONDx.
Contemp Oncol (Pozn)
October 2024
Department of Oncology, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Introduction: Breast cancer (BC) is among the most frequently diagnosed malignant tumours in females. The optimal treatment of early HR+, HER2-, and lymph node-negative (N0) BC remains challenging. Since individual assessment of recurrence risk and expected benefits from adjuvant chemotherapy (CT) based on clinicopathological features alone appear inadequate, gene expression profiling tests have been developed.
View Article and Find Full Text PDFImpact of the 21-gene recurrence score testing on chemotherapy selection and clinical outcomes in T3N0 luminal breast cancer.
Expert Rev Anticancer Ther
November 2024
Department of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Background: The role of 21-gene recurrence score (RS) testing on chemotherapy decision-making and survival outcomes for T3N0 luminal breast cancer (BC) remains unclear. This study aimed to investigate the effect of RS testing in chemotherapy selection and prognosis in these patients.
Research Design And Methods: Patients diagnosed with T3N0 luminal BC were included from the Surveillance, Epidemiology, and End Results Oncotype database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!